Priority Review for Bayer’s Drug – Analyst Blog
Posted on February 14, 2013 at 17:25 PM EST
Bayer announced that the FDA granted priority review to the NDA for its oncology candidate radium-223 dichloride
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here